Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up
Karen P. Alexander, MD, FACCa,
L. Kristin Newby, MD, FACC
,
Anne S. Hellkamp, MS
,
Robert A. Harrington, MD, FACC
,
Eric D. Peterson, MD, MPH, FACCa,
Steve Kopecky, MD, FACC
,
Antoly Langer, MD, FACC
,
Patrick OGara, MD, FACC||,
Christopher M. OConnor, MD, FACC
,
Robert N. Daly, MS, PhD¶,
Robert M. Califf, MD, FACC
,
Steven Khan, MD, FACC# and
Valentin Fuster, MD, FACC**
a Outcomes Research and Assessment Group, The Duke Clinical Research Institute, Durham, North Carolina, USA
The Duke Clinical Research Institute, Durham, North Carolina, USA
Mayo Clinic, Rochester, Minnesota, USA
St. Michaels Hospital, Toronto, Canada
|| Brigham and Womens Hospital, Boston, Massachusetts, USA
¶ Dupont Pharmaceuticals, Wilmington, Delaware, USA
# Cedars-Sinai Medical Center, Los Angeles, California, USA
** Mount Sinai Medical Center, New York, New York, USA

View larger version (8K):
[in a new window]
|
Figure 1 Cumulative incidence of death/recurrent myocardial infarction/unstable angina requiring hospitalization during follow-up period by hormone replacement therapy use category.
|
|
Copyright © 2001 by the American College of Cardiology Foundation.